Press Releases

Press Releases

All Releases
Mar 05, 2014
Webcast Available Through Ophthotech Website NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Barclays Capital Global Healthcare Conference
Mar 04, 2014
-Webcast to Begin at 8:30 a.m. Eastern time - NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that the Company will host a live webcast in conjunction with its Research and Development (R&D) Day on Friday, March 7, 2014 , beginning at 8:30 a.m. ET.
Feb 27, 2014
Conference Call and Webcast Today, February 27 , at 8:00 a.m. ET NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development
Feb 24, 2014
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (Nasdaq:OPHT) today announced that its fourth quarter and year ended December 31, 2013 , financial results will be released on Thursday, February 27, 2014 . Following the announcement, Ophthotech's management will host a live conference call and
Feb 18, 2014
NEW YORK --(BUSINESS WIRE)-- Ophthotech Corporation (NASDAQ:OPHT) announced today the closing of its previously announced registered public offering of 2,628,571 shares of its common stock at a price to the public of $31.50 per share, before underwriting discounts.
Feb 11, 2014
New York, NY— Feb. 11, 2014 —Ophthotech Corporation (NASDAQ: OPHT) announced today the pricing of an underwritten public offering of 2,285,714 shares of common stock at a public offering price of $31.50 per share, before underwriting discounts.
Feb 10, 2014
Ophthotech Corporation Announces Proposed Public Offering of Common Stock New York, NY-Feb. 10, 2014 -Ophthotech Corporation (NASDAQ: OPHT) announced today that it has commenced an underwritten public offering of 1,900,000 shares of its common stock. In addition, certain stockholders of the company
Jan 24, 2014
Ophthotech Corporation Receives $41.7 Million in Second Tranche in Royalty Financing from Novo A/S New York, NY—January 24, 2014 —Ophthotech Corporation (Nasdaq: OPHT) today announced that it has received payment of approximately $41.7 million in a second tranche in royalty financing
Oct 30, 2013
Ophthotech to Report Third Quarter 2013 Results and Host Conference Call on Wednesday, November 13, 2013 NEW YORK, NY – October 30, 2013 – Ophthotech Corporation (Nasdaq: OPHT) today announced that the company will report its financial results for the third quarter ended September 30,
Sep 30, 2013
Ophthotech Closes Initial Public Offering NEW YORK, NY – September 30, 2013 – Ophthotech Corporation today announced the closing of its initial public offering of 8,740,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts, including
Sep 24, 2013
Ophthotech Corporation Prices Initial Public Offering NEW YORK, NY – September 24, 2013 – Ophthotech Corporation today announced the pricing of its initial public offering of 7,600,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts.
Aug 29, 2013
Ophthotech Enrolls First Patient in Phase 3 Clinical Trial of Fovista™ Anti-PDGF Therapy in Combination with Anti-VEGF Therapy for Wet AMD New York, NY – August 29, 2013 – Ophthotech Corporation today announced the initiation of patient enrollment in a pivotal Phase 3 clinical
Aug 15, 2013
Ophthotech Corporation Files Registration Statement for Proposed Initial Public Offering New York, NY—August 15, 2013 – Ophthotech Corporation today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”)
Jan 03, 2013
Ophthotech to Present at 31st Annual J.P. Morgan Healthcare Conference Princeton, NJ and New York, NY – January 3, 2013 – Ophthotech Corp. announced today that the company will participate in the 31st Annual J.P. Morgan Healthcare Conference to be held Jan. 7-10, 2013.
Oct 24, 2012
Positive Results from Phase 2b Study of Ophthotech’s Novel Anti-PDGF Combination Agent Fovista™ to be Presented at AAO Retina Subspecialty Day Princeton, NJ – October 24, 2012 – Ophthotech Corporation today announced that data from a large, prospective, randomized,
Jan 03, 2012
Ophthotech to Present at 30th Annual J.P. Morgan Healthcare Conference Princeton, NJ and New York, NY – January 3, 2012 – Ophthotech Corp. announced today that the company will participate in the 30th Annual J.P. Morgan Healthcare Conference in San Francisco.